Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAnpario Regulatory News (ANP)

Share Price Information for Anpario (ANP)

Share Price is delayed by 15 minutes
Get Live Data
520.00    5.00 (0.97%)
Bid:
510.00
Ask:
530.00
Spread: 20.00 (3.922%)
Market Cap: £85.47m
ANP Live PriceLast checked at - London Stock Exchange

Intraday Anpario Share Chart

Full year trading statement

10 Jan 2025 07:00

RNS Number : 8294S
Anpario PLC
10 January 2025
 

THIS ANNOUNCEMENT RELATES TO THE DISCLOSURE OF INFORMATION THAT QUALIFIED OR MAY HAVE QUALIFIED AS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018.

 

 

Anpario plc("Anpario", the "Group" or the "Company")

 

Full year trading statement

 

Anpario plc (AIM:ANP), the independent manufacturer of natural sustainable animal feed additives for health, nutrition and biosecurity, provides the following trading update for the year ended 31 December 2024 ("FY 2024"). The figures set out in this announcement remain subject to audit.

 

Trading update

The Group, including three months of trading for Bio-Vet Inc., delivered a stronger than expected operating performance in the second half of 2024. Year-end sales were higher than anticipated, and the Group now expects revenue for the 12 months ended 31 December 2024 to be approximately £37.5m* (31 December 2023: £31.0m). This strong performance in revenue combined with the Group's high operational gearing and favourable year-end foreign exchange movements, will result in adjusted EBITDA being ahead of current market expectations*.

 

Bio-Vet Inc. had a strong final quarter due to heightened demand for its products, which support the health of dairy cows affected by avian influenza, and our Middle East and Africa segment delivered an outstanding sales performance.

 

Financial position

Our financial position remains strong, with year-end cash balances of £10.5m* (31 December 2023: £10.6m), after accounting for the acquisition of Bio-Vet Inc. and associated land and buildings for an initial cash consideration of US$6.3m, on a debt-free basis, which completed in September 2024.

 

Our strong balance sheet enables the Group to invest in innovative natural product solutions, expand our global reach and explore earnings enhancing and complementary acquisitions to continue the profitable development of the Group. We remain confident in our ability to capitalise on growth opportunities, delivering long-term benefits to all stakeholders.

 

FY2024 Results

The Group expects to publish its FY 2024 final results on or around 26 March 2025.

 

 

 

*Analyst consensus for FY 2024 immediately prior to this announcement was Revenue of £35.25m, EBITDA of £5.7m and net cash of £7.2m.

 

Enquiries

 

Anpario plc

Richard Edwards, Chief Executive Officer

+44(0)7776 417 129

Marc Wilson, Group Finance Director

+44(0)1909 537 380

Shore Capital

 

(Nominated Adviser and Broker)

+44 (0) 20 7408 4090

Stephane Auton

Corporate Advisory

David Coaten

Tom Knibbs

Henry Willcocks

Corporate Broking

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUPUUUGUPAPWB
Date   Source Headline
30th Jan 20207:00 amBUSTrading Statement
20th Jan 202010:05 amRNSHolding(s) in Company
17th Jan 20204:55 pmRNSBlock listing Interim Review
17th Jan 20209:40 amRNSHolding(s) in Company
13th Jan 202010:31 amRNSHolding(s) in Company
8th Jan 20203:39 pmRNSHolding(s) in Company
6th Jan 202011:04 amRNSHolding(s) in Company
18th Nov 20195:30 pmRNSHolding(s) in Company
5th Nov 20199:44 amRNSHolding(s) in Company
11th Sep 20197:00 amBUSHalf-year Report
14th Aug 201911:10 amRNSHolding(s) in Company
13th Aug 20196:08 pmRNSHolding(s) in Company
17th Jul 201910:41 amRNSBlock listing Interim Review
27th Jun 20194:23 pmRNSResult of AGM
27th Jun 20197:00 amRNSAGM Statement
21st Jun 20197:00 amRNSTotal Voting Rights
5th Jun 201910:47 amRNSDirector/PDMR Shareholding
4th Jun 20195:35 pmRNSPosting of Annual Report and Notice of AGM
24th Apr 20193:27 pmRNSHolding(s) in Company
17th Apr 20192:04 pmRNSHolding(s) in Company
2nd Apr 201910:33 amRNSTotal Voting Rights
8th Mar 201911:06 amRNSFinal Results
6th Mar 20197:00 amBUSFinal Results
5th Mar 20194:17 pmRNSTotal Voting Rights
29th Jan 20197:00 amRNSPre-Close Trading Statement
17th Jan 201912:17 pmRNSBlock listing Interim Review
6th Dec 20182:30 pmRNSHolding(s) in Company
6th Dec 20182:25 pmRNSHolding(s) in Company
2nd Oct 20183:51 pmRNSTotal Voting Rights
5th Sep 20187:00 amRNSHalf-year Report
31st Jul 20189:54 amRNSHolding(s) in Company
19th Jul 20183:30 pmRNSBlock listing Interim Review
28th Jun 20184:05 pmBUSResult of AGM
28th Jun 20187:00 amRNSAGM Statement
5th Jun 20183:58 pmRNSAnnual Report and Notice of AGM
4th Jun 20183:17 pmRNSTotal Voting Rights
4th May 201812:05 pmRNSTotal Voting Rights
9th Apr 20188:25 amRNSTotal Voting Rights
7th Mar 20187:00 amBUSFinal Results
5th Mar 20183:16 pmRNSHolding(s) in Company
5th Feb 20182:21 pmRNSTotal Voting Rights
29th Jan 20187:00 amRNSTrading Statement
19th Jan 20182:32 pmRNSBlock listing Six Monthly Return
22nd Nov 20174:53 pmRNSEmployee Share Plan and Directors' Dealing
20th Oct 20177:00 amRNSDirectorate Change
21st Sep 20173:30 pmRNSDirector/PDMR Shareholding
21st Sep 20173:30 pmRNSDirector/PDMR Shareholding
19th Sep 20177:00 amBUSHalf-year Report
28th Jul 20179:46 amRNSBlock Listing Return
18th Jul 20174:58 pmRNSDirector/PDMR Shareholding and Issue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.